Daily Market Updates: Newly listed stock has 27% upside potential! JM Financial issues buy call; Check target price and key triggers

Global Markets

Home›Global Markets›North America›Newly listed stock has 27% upside potential! JM Financ…

Newly listed stock has 27% upside potential! JM Financial issues buy call; Check target price and key triggers

Reported · Written up by our desk · North America

JM Financial initiated coverage of Symbiotec Pharmalab with a Buy rating and a ₹1,622 target price, implying about 27% upside. It expects new capacity, CDMO and complex injectable growth to lift revenue, EBITDA and profit through FY29.

← Newer storyJapan's top yen stablecoin falls short of its target in a disappointi…Older story →Bitcoin drops below $80,000 as crypto ignores Asian tech rally, Fed m…

More like this

Global MarketsWalmart says AI training is boosting confidence with the technology among its 2.1 million associates

Global MarketsBullish Treasury Bets Face Reversal Risk From Hawkish Fed

Global MarketsAlibaba wins preliminary injunction against Pentagon lobbying rule

Global Markets5 things to watch out for in 2027 US defence bill aimed at countering China

Global MarketsNovogratz Says Credit Market Is Reaching ‘Peak Nervousness’

Sources

LiveMint MarketsNewly listed stock has 27% upside potential! JM Financial issues buy call; Check target price and key triggers

Global Markets

Newly listed stock has 27% upside potential! JM Financial issues buy call; Check target price and key triggers

More like this

Sources

Get the close, explained.